Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
NCT ID: NCT05120167
Last Updated: 2023-07-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
288 participants
INTERVENTIONAL
2021-09-29
2022-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)
NCT03241680
Low-cost Imaging Technology for Global Prevention of Cervical Cancer
NCT05078528
Self-Collection and Human Papillomavirus (HPV) Testing in Unscreened Women: a Feasibility Study in Brazil
NCT03713697
Cervical Cancer Screening Study in Brazil
NCT02335372
A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
NCT05282745
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Data Analysis Methodology: The information bank generated by Red Cap will be reviewed to assess possible inconsistencies or filling errors that will be corrected using the original information recorded in the medical records. The final digital spreadsheet will be worked on to replace the identification of the subjects with an order number. Only the researchers will know the origin of the information. This final spreadsheet without identification will be used for statistical analysis. Initially, a descriptive statistical analysis will be performed with the calculation of proportions and the respective 95% confidence intervals (95% CI) for the variables studied and their categories, according to the additional diagnostic methods and the final diagnosis. For the descriptive analysis, the chi-square and Fisher tests will be used, when appropriate, considering a p-value less than 0.05 for statistical significance. Next, a diagnostic test type analysis will be performed with the calculation of sensitivity (SENS), specificity (SPEC), negative predictive value (NPV), and positive predictive value (PPV) of each additional procedure in defining the final diagnosis. The accuracy of the various associations between the methods will be tested. The G\*Power v. 3.1.9.2 software will be used to carry out these statistical procedures. Histology or 12-month follow-up, at semi-annual intervals, with negative colposcopy and cytology results will be used as the gold standard for test performance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endocervical cytology performed by liquid-based cytology
Endocervical sample collected by brushing and preserved in a liquid base, and evaluated as cytology.
Endocervical liquid-base cytology
Endocervical sample collected by brushing and preserved in a liquid-base.
Endocervical cell block from a canal sample preserved in a buffered formalin base
Endocervical sample collected by brushing and preserved in a buffered formalin base for obtaining a "cell block", and evaluated similarly as histology.
Endocervical cell block
Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a "cell block" and evaluated as histology.
Endocervical curettage
Endocervical curettage sample preserved in buffered formalin and evaluated by histology.
Endocervical curettage
Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Endocervical liquid-base cytology
Endocervical sample collected by brushing and preserved in a liquid-base.
Endocervical cell block
Endocervical sample collected by endocervical brush and preserved in a buffered formalin base for obtaining a "cell block" and evaluated as histology.
Endocervical curettage
Endocervical sample obtained by curettage, preserved in buffered formalin, and evaluated as histology.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-pregnant
Exclusion Criteria
* total hysterectomy (extirpation of the cervix);
* cervical stenosis or imperviousness near the external orifice.
25 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cirbia Silva Campos Teixeira
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cirbia Silva Campos Teixeira
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Cirbia SC Teixeira, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital de Cancer de Barretos
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Cancer de Barretos
Campo Grande, Mato Grosso do Sul, Brazil
Sandra Moretti Jusselino Maniçoba Palopoli
Nova Andradina, Mato Grosso do Sul, Brazil
Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
Hospital de Cancer de Barretos
Campinas, São Paulo, Brazil
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, Sundstrom K, Dillner J, Sparen P. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020 Oct 1;383(14):1340-1348. doi: 10.1056/NEJMoa1917338.
Possati-Resende JC, Fregnani JH, Kerr LM, Mauad EC, Longatto-Filho A, Scapulatempo-Neto C. The Accuracy of p16/Ki-67 and HPV Test in the Detection of CIN2/3 in Women Diagnosed with ASC-US or LSIL. PLoS One. 2015 Jul 31;10(7):e0134445. doi: 10.1371/journal.pone.0134445. eCollection 2015.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. doi: 10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F.
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003 Jan;16(1):1-17. doi: 10.1128/CMR.16.1.1-17.2003.
Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007 Aug 1;121(3):621-32. doi: 10.1002/ijc.22527.
Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004 Aug 20;111(2):278-85. doi: 10.1002/ijc.20244.
Zeferino LC, Derchain SF. Cervical cancer in the developing world. Best Pract Res Clin Obstet Gynaecol. 2006 Jun;20(3):339-54. doi: 10.1016/j.bpobgyn.2006.01.018. Epub 2006 Mar 24.
Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002 Sep 14;325(7364):572. doi: 10.1136/bmj.325.7364.572.
Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, Frazer IH, Canfell K. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019 Jan;4(1):e19-e27. doi: 10.1016/S2468-2667(18)30183-X. Epub 2018 Oct 2.
Derchain S, Teixeira JC, Zeferino LC. Organized, Population-based Cervical Cancer Screening Program: It Would Be a Good Time for Brazil Now. Rev Bras Ginecol Obstet. 2016 Apr;38(4):161-3. doi: 10.1055/s-0036-1582399. Epub 2016 Apr 18. No abstract available.
El-Zein M, Gotlieb W, Gilbert L, Hemmings R, Behr MA, Franco EL; STAIN-IT Study Group. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. Int J Cancer. 2021 Jan 15;148(2):492-501. doi: 10.1002/ijc.33250. Epub 2020 Aug 24.
Fonseca FV, Tomasich FD, Jung JE, Maestri CA, Carvalho NS. The role of P16ink4a and P53 immunostaining in predicting recurrence of HG-CIN after conization treatment. Rev Col Bras Cir. 2016 Feb;43(1):35-41. doi: 10.1590/0100-69912016001008. English, Portuguese.
Waxman AG, Chelmow D, Darragh TM, Lawson H, Moscicki AB. Revised terminology for cervical histopathology and its implications for management of high-grade squamous intraepithelial lesions of the cervix. Obstet Gynecol. 2012 Dec;120(6):1465-71. doi: 10.1097/aog.0b013e31827001d5.
Goksedef BP, Api M, Kaya O, Gorgen H, Tarlaci A, Cetin A. Diagnostic accuracy of two endocervical sampling method: randomized controlled trial. Arch Gynecol Obstet. 2013 Jan;287(1):117-22. doi: 10.1007/s00404-012-2542-9. Epub 2012 Sep 5.
Tuon FF, Bittencourt MS, Panichi MA, Pinto AP. [Sensibility and specificity of cytology and colposcopy exams with the histological evaluation of cervical intraepithelial lesions]. Rev Assoc Med Bras (1992). 2002 Apr-Jun;48(2):140-4. doi: 10.1590/s0104-42302002000200033. Portuguese.
Undurraga M, Catarino R, Navarria I, Ibrahim Y, Puget E, Royannez Drevard I, Pache JC, Tille JC, Petignat P. User perception of endocervical sampling: A randomized comparison of endocervical evaluation with the curette vs cytobrush. PLoS One. 2017 Nov 6;12(11):e0186812. doi: 10.1371/journal.pone.0186812. eCollection 2017.
Related Links
Access external resources that provide additional context or updates about the study.
Organization WH. International Agency for Reseach on Cancer. Cervix uteri Source: Globocan 2020. Internet, 2020.
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Estimativa para 2020-22 do câncer do colo uterino no Brasil e diferentes regiões, 2020.
ABPTGIC. Associação Brasileira de Patologia do Trato Genital Inferior e Colposcopia. Novas estratégias para o rastreamento cervical baseadas no teste para hpv, 2021.
FEBRASGO. Federação Brasileira das Associações de Ginecologia e Obstetrícia Internet. Rastreamento para câncer de colo uterino: o que há de novo?, 2020.
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Diretrizes para o rastreamento do Câncer do Colo do útero. Rio de Janeiro: INCA, 2016, 2016.
Miranda W, Miziara F, Saieg M, and Fronza H. Atualização Nomeclatura Brasileira para Laudos citopatológicos do colo uterino e Ano-Gentiais. Sociedade Brasileira de Citopatologia. 2020.
Organization WH. International Agency for Reseach on Cancer. Citopatologia do colo uterino - atlas digital: Sistema Bethesda de 2001. Internet, 2001.
Brasil. Ministério da Saúde. Instituto Nacional de Câncer. Resolução CNS 466/12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
49006721.5.0000.5437
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.